The ability of next-generation sequencing (NGS) technologies to detect low frequency HIV-1 drug resistance mutations (DRMs) not detected by dideoxynucleotide Sanger sequencing has potential advantages for improved patient outcomes. We compared the performance of an in vitro diagnostic (IVD) NGS assay, the Sentosa SQ HIV genotyping assay for HIV-1 genotypic resistance testing, with Sanger sequencing on 138 protease/reverse transcriptase (RT) and 39 integrase sequences. The NGS assay used a 5% threshold for reporting low-frequency variants. The level of complete plus partial nucleotide sequence concordance between Sanger sequencing and NGS was 99.9%. Among the 138 protease/RT sequences, a mean of 6.4 DRMs was identified by both Sanger and NGS, a mean of 0.5 DRM was detected by NGS alone, and a mean of 0.1 DRM was detected by Sanger sequencing alone. Among the 39 integrase sequences, a mean of 1.6 DRMs was detected by both Sanger sequencing and NGS and a mean of 0.15 DRM was detected by NGS alone. Compared with Sanger sequencing, NGS estimated higher levels of resistance to one or more antiretroviral drugs for 18.2% of protease/RT sequences and 5.1% of integrase sequences. There was little evidence for technical artifacts in the NGS sequences, but the G-to-A hypermutation was detected in three samples. In conclusion, the IVD NGS assay evaluated in this study was highly concordant with Sanger sequencing. At the 5% threshold for reporting minority variants, NGS appeared to attain a modestly increased sensitivity for detecting low-frequency DRMs without compromising sequence accuracy.
T
wo factors motivate the increased use of next-generation sequencing (NGS) for diagnosing HIV-1 drug resistance in both research and clinical settings. First, the cost of NGS can be considerably lower than that of dideoxynucleotide Sanger sequencing should a sufficient number of samples be tested in the same sequencing run (1, 2) . Second, the ability of NGS to detect low-frequency drug resistance mutations (DRMs) not detected by Sanger sequencing has potential advantages for improved patient outcomes (3) .
However, Sanger sequencing has been used for 2 decades to diagnose HIV-1 drug resistance and has been shown to be highly reproducible and interpretable in clinical settings. In contrast, NGS technologies have been rapidly evolving, resulting in changes to both laboratory and bioinformatics analysis protocols (4) . Moreover, no in vitro diagnostic (IVD) assay for HIV-1 genotypic resistance testing using NGS has been approved by the U.S. Food and Drug Administration (FDA). In this study, we compared went PR/RT and IN sequencing, and 5 that underwent just IN sequencing. Thus, 138 samples underwent PR/RT sequencing and 34 underwent IN sequencing by both Sanger sequencing and NGS. In all samples, both Sanger sequencing and NGS encompassed the entire PR sequence, the first 250 positions of the RT sequence, and the entire IN sequence. Twelve samples (8.4% of 143) had non-B subtypes, including subtypes C (n ϭ 4), CRF01_AE (n ϭ 3), A (n ϭ 2), G (n ϭ 1), CRF02_AG (n ϭ 1), and CRF07_BC (n ϭ 1). The VL was available for 127 (88.8%) of 143 samples. The median VL for these samples was 3.8 log 10 copies/ml (IQR, 3.1 to 4.5 log 10 copies/ml).
Treatment histories were available for 112 individuals undergoing PR/RT sequencing. Among these individuals, the median numbers of NRTIs, NNRTIs, and PIs were 4, 1, and 2, respectively. Among 29 individuals undergoing IN sequencing for whom the treatment history was available, the median number of INSTIs received was 1. Table 1 lists each of the NRTI, NNRTI, PI, and INSTI DRMs detected by Sanger sequencing according to its frequency in the tested samples. The samples contained 137 distinct DRMs: 40 NRTI-, 34 NNRTI-, 41 PI-, and 22 INSTI-associated DRMs. Table S2 in the supplemental material lists the DRMs and their penalty scores for the most commonly used ARVs. There was a high correlation between the proportions of DRMs in this data set and those from ARV-treated persons in HIVDB (r 2 Ͼ 0.8; P Ͻ 0.001).
Nucleotide sequence concordance and sequence ambiguities. In both the PR/RT and IN sequences, the nucleotide sequences determined by Sanger sequencing and NGS were highly concordant: 98.37% of nucleotides were identical, 1.58% were partially discordant, and 0.05% were completely discordant. Not surprisingly, the median number of IUPAC ambiguities was significantly higher in the sequences determined by NGS than those determined by Sanger sequencing: 2.1 (IQR, 1.0 to 3.5) versus 1.1 (IQR, 0.4 to 1.8) (P Ͻ 0.001, Mann-Whitney U test). The median 1.1% level of IUPAC ambiguities detected by Sanger sequencing is similar to the proportions of 0.7%, 1.1%, and 1.1% reported from three laboratories performing Sanger sequencing on similar heavily treated patients (7, 8) . The higher proportion of ambiguities by NGS results from its lower threshold for detecting variants.
Mutations, DRMs, and drug resistance interpretations. Among the 138 PR/RT sequences, a mean of 24.2 mutations, defined as differences from the subtype B amino acid consensus sequence, was detected by both Sanger sequencing and NGS (Table 2) . NGS identified a mean of 4.4 mutations not detected by Sanger sequencing, whereas Sanger sequencing identified a mean of 0.6 mutation not detected by NGS (P Ͻ 0.001, Student's t test). Among the 39 IN sequences, a mean of 12.1 mutations was identified by both Sanger sequencing and NGS (Table 2) . NGS identified a mean of 2.7 mutations not detected by Sanger sequencing, whereas Sanger sequencing identified a mean of 1.2 mutations not detected by NGS (P ϭ 0.03, Student's t test).
Among the 138 PR/RT sequences, a mean of 6.4 drug resistance mutations (DRMs) was identified by both Sanger sequencing and NGS (Table 2) . NGS identified a mean of 0.5 mutation not detected by Sanger sequencing, whereas Sanger sequencing detected a mean of 0.1 mutation not detected by NGS (P Ͻ 0.001, Student's t test). Among the 39 IN sequences, a mean of 1.6 DRMs was identified by both Sanger sequencing and NGS (Table 2) . NGS identified a mean of 0.2 DRM detected by Sanger sequencing, whereas Sanger sequencing identified a mean of 0.03 DRM not detected by NGS (P ϭ 0.09, Student's t test). Among the 11 DRMs detected by Sanger sequencing but not NGS, each was present as a mixture by Sanger sequencing and 6 were present below the 5% threshold when the raw NGS reads were examined.
On average, there was no significant difference between Sanger sequencing and NGS in the predicted levels of resistance to any of the NRTIs, NNRTIs, PIs, and INSTIs (Table 3) . However, for the 138 PR/RT samples, NGS detected a higher level of NRTI resistance for 6.2% (n ϭ 9) of samples, a higher level of NNRTI resistance for 11.2% (n ϭ 16) of samples, and a higher level of PI resistance for 4.1% (n ϭ 6) of samples than Sanger sequencing (Tables 4 to 6 ). In contrast, Sanger sequencing detected higher levels of NRTI, NNRTI, and PI resistance for 0.7% (n ϭ 1), 1.4% (n ϭ 2), and 0.7% (n ϭ (Table 7) . Quality control comparison. There was no significant difference in the mean number of signature APOBEC mutations per sequence between Sanger sequencing and NGS in either PR/RT sequences (0.02 for Sanger sequencing versus 0.14 for NGS; P ϭ 0.2, paired Student's t test) or IN sequences (0.05 for Sanger sequencing versus 0.41 for NGS; P ϭ 0.06). One PR/RT sequence and three IN sequences determined by NGS had three or more signature APOBEC mutations. Sample B2-11 had 12 signature APOBEC mutations, including six stop codons. Samples B3-25, B1-33, and B3-02 had five, four, and three signature APOBEC mutations, respectively. In contrast, no sequence determined by Sanger sequencing had more than two signature APOBEC mutations. The PR/RT sample B2-11, which had 12 signature APOBEC mutations, including six stop codons at the default 5% threshold, had no signature APOBEC mutations or stop codons at a 20% threshold. This sample had two NNRTI resistance mutations, G190E and M230I, which are among the few NNRTI resistance mutations that can be caused by APOBEC (Table 5 ). G190E was detected by both Sanger sequencing and NGS, but M230I was detected only by NGS (at the 5% threshold but not the 20% threshold). This sample had a VL of 3.8 log copies/ml and a subtype B virus.
The mean number of highly unusual mutations per sequence in PR/RT was higher for the sequences determined by NGS than for the sequences determined by Sanger sequencing (0.75 versus 0.29; P ϭ 0.002, paired Student's t test). There was no significant difference in the mean number of highly unusual mutations in the IN sequences (0.44 versus 0.38; P ϭ 0.8, paired Student's t test). Among the 138 PR/RT sequences, the highest number of highly unusual mutations was four for Sanger sequencing. For NGS, five samples had a higher number of highly unusual mutations, including one with six and four with five highly unusual mutations.
DISCUSSION
This study is one of the largest comparisons of HIV-1 genotypic resistance testing conducted using Sanger sequencing and NGS and one of the few comparing Sanger sequencing to an IVD NGS assay. Despite the use of different methods for sample preparation and amplification, the level of complete plus partial nucleotide sequence concordance between Sanger sequencing and NGS was extraordinarily high, matching the 99.9% concordance rate reported in a previous study comparing different Sanger sequencing protocols (8) . Compared with Sanger sequencing, NGS detected significantly more DRMs per sequence and estimated higher levels of resistance to one or more ARVs for 18.2% of PR/RT sequences and 5.1% of IN sequences.
Sanger sequencing usually detects HIV-1 variants present in proportions above 20%, with a range of 10% to 30%, depending on the nucleotide context (7, (9) (10) (11) (12) . In contrast, the proportion at which variants can be detected by NGS depends on the selected threshold. Although detection thresholds as low as 1% have often been used in research studies, many of these studies excluded samples with low plasma virus levels (13) (14) (15) (16) (17) . Two recent descriptions of HIV-1 NGS analysis pipelines suggested using a detection threshold of 5% to minimize technical artifacts (18, 19) . Because of its extraordinary sensitivity, NGS is prone to two types of artifacts that occur uncommonly during Sanger sequencing: PCR error and APOBEC-mediated G-to-A hypermutation. PCR errors commonly occur during nested PCR but are rarely present at levels high enough to be detected by Sanger sequencing (20) (21) (22) (23) . In contrast, PCR errors are detected by NGS if the detection threshold is set too low. Indeed, if the number of amplifiable cDNA templates is low due to a low VL and/or inefficient RNA extraction, reverse transcription, or PCR, then much of the observed variability in an NGS sequence will represent PCR error (21, 22, 24) . Indeed, studies using the Primer ID approach, which adds a unique label to each cDNA molecule, shows that the depth of NGS does not necessarily lead to the reliable detection of low-frequency variants (21, 25, 26) .
NGS is also more likely than Sanger sequencing to detect low-level APOBECmediated G-to-A hypermutation, particularly in samples contaminated with proviral DNA (27) (28) (29) . Hypermutated viruses are unlikely to be functional and have not been shown to contribute to virological failure (27) (28) (29) (30) . There are 13 DRMs that can be caused by APOBEC-mediated hypermutation, including D30N, M46I, and G73S in PR; D67N, E138K, M184I, G190SE, and M230I in RT; and E138K, G118R, and G163KR in IN. Determining whether a sequence contains an APOBEC-mediated G-to-A hypermutation is necessary for interpreting the significance of these DRMs.
We have hypothesized that an inappropriately low detection threshold for a sample a Predicted levels of drug resistance according to the HIVDB genotypic resistance interpretation system, which were scored as follows: 1 for susceptible, 2 for potential low-level resistance, 3 for low-level resistance, 4 for intermediate resistance, and 5 for high-level resistance. For an additional 5 sequences, NGS detected two mutations at a DRM position for which Sanger sequencing detected a single mutation. However, the additional mutation did not result in a change in the estimated level of drug resistance. 3FTC, lamivudine and emtricitabine; ABC, abacavir; AZT, zidovudine; TDF, tenofovir.
can be determined in a post hoc analysis by counting its number of highly unusual and signature APOBEC mutations at different thresholds (6, 31) . The presence of a large number of highly unusual mutations above a threshold suggests that the threshold is too low and that some of the low-frequency mutations are PCR errors. Likewise, the presence of a large number of signature APOBEC mutations above a threshold suggests that those DRMs that can be caused by APOBEC-mediated hypermutation may not reflect ARV selection pressure.
In this study, we identified one PR/RT sample and three IN samples with evidence for an APOBEC-mediated G-to-A hypermutation and five PR/RT samples with a slightly greater number of highly unusual mutations by NGS than by Sanger sequencing. The one hypermutated PR/RT sample was readily identifiable, and our post hoc analysis showed that a cutoff of 20% was appropriate for this sample. The relatively infrequent detection of signature APOBEC mutations and highly unusual mutations by NGS in this study is consistent with the conservative 5% threshold. 188L  103N  5  2  5  B3-36  98G, 101E, 103N, 190A  225H  5  4  5  B2-28  179E, 188L  108I  5  3  5  B2-29  98G, 103N, 108I, 221Y, 227L  238N  5  3  4  B1-04  100I, 103N, 225H  108I  5  4  5  B2-49  101P, 230L, 238N  101E, 138K, 181C  5  5  5 a Predicted levels of drug resistance according to the HIVDB genotypic resistance interpretation system, which were scored as follows: 1 for susceptible, 2 for potential low-level resistance, 3 for low-level resistance, 4 for intermediate resistance, and 5 for high-level resistance. EFV, efavirenz; ETR, etravirine; RPV, rilpivirine. b Sample B2-11 had evidence for an APOBEC-mediated G-to-A hypermutation. Both G190E (which was also detected by Sanger sequencing) and M230I (which was detected only by NGS) are DRMs that occur in the APOBEC dinucleotide context.
Low-frequency DRMs include those that were once dominant in an individual's virus population as a result of transmitted or acquired resistance but that, in the absence of drug pressure, were outgrown by more fit variants (32) (33) (34) and those that have emerged under selective drug pressure but that have not reached levels detectable by Sanger sequencing (27, 35) . In this study of samples obtained primarily from heavily treated individuals with multiple DRMs detectable by Sanger sequencing, NGS detected a Predicted levels of drug resistance according to the HIVDB genotypic resistance interpretation system, which were scored as follows: 1 for susceptible, 2 for potential low-level resistance, 3 for low-level resistance, 4 for intermediate resistance, and 5 for high-level resistance. For an additional two sequences, NGS detected two mutations at a DRM position for which Sanger detected a single mutation. However, the additional mutation did not result in a change in the estimated level of drug resistance. ATV/r, ritonavir-boosted atazanavir; DRV/r, ritonavir-boosted darunavir; LPV/r, ritonavir-boosted lopinavir. (13, 16, 36, 37) . The strongest evidence for the clinical significance of low-frequency DRMs has been for the CXCR5 inhibitor (38) and NNRTI (39, 40) classes. One meta-analysis and two subsequent case-control and cohort studies have shown that low-frequency NNRTI DRMs are associated with an increased risk of virological failure on a first-line NNRTIcontaining regimen (15, 39, 41) . The cohort study showed an increased risk of virological failure associated with low-frequency variants present at levels above 5% but not at lower levels (41) . Low-frequency accessory PI-associated DRMs have not been shown to reduce the response to a first-line ritonavir-boosted ATV-or ritonavir-boosted DRV-containing regimen (42) .
Low-frequency DRMs have been associated with an increased risk of virological failure in one retrospective salvage therapy study (13) but demonstrated only a trend toward increased virological failure in a second study of salvage therapy with the potent combination of ritonavir-boosted darunavir, raltegravir, and etravirine (37) . Low-frequency DRMs also appear to be more likely to be clinically significant in patients with a treatment history compatible with the DRM, possibly because in this setting the low-frequency DRMs are less likely to be artifactual and more likely to be linked to compensatory mutations (16, 36, 40) .
In conclusion, this study demonstrates a high concordance rate between NGS and Sanger sequencing. Despite using a conservative 5% threshold for low-frequency variants, NGS still detected a mean of an additional 0.5 PR/RT DRM and 0.1 IN DRM per sequence, resulting in a predicted increased level of resistance to one or more ARVs for 18% of PR/RT sequences and 5% of IN sequences. Additional studies are needed to elucidate the clinical significance of different low-frequency DRMs, although it is likely that those DRMs causing the greatest reductions in susceptibility to ARVs with low genetic barriers to resistance will be the most clinically relevant.
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